# A Study of EBC-129 in Advanced Solid Tumours

> **NCT05701527** · PHASE1 · RECRUITING · sponsor: **EDDC (Experimental Drug Development Centre), A*STAR Research Entities** · enrollment: 98 (estimated)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** EBC-129
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05701527
- **Lead sponsor:** EDDC (Experimental Drug Development Centre), A*STAR Research Entities
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-28
- **Primary completion:** 2026-12-24
- **Final completion:** 2026-12-24
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701527, "A Study of EBC-129 in Advanced Solid Tumours". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT05701527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*